Mr Christopher Schneider
Graz (Austria)
The anti-cancer tyrosine kinase inhibitor sorafenib reduces cardiac contractile force by reducing cardiomyocyte calcium transient amplitude.
Event: ESC Congress 2017
Topic: Cardiotoxicity of drugs
Session: Chronic heart failure (CHF)
ESC 365 is supported by
